ITCMDBv1
Clinical TrialID 5618

Study With Mitomycin c/5-FU/FA in Pretreated Gastrointestinal Cancer Patients With Metastases (>= Second-line Treatment)

NCT00289445

Gastrointestinal Neoplasms|Neoplasm Metastasis

Back to Browse

Relationship Network

Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.

Click a node to open it in a new tab
Trial: 1Ingredient: 1Links: 1
Arranging relationship network...

Record Fields

Scalar fields from the final clinical_trial record.

Clinical Trial Id
5618
Evidence Id
5618
Core Evidence Id
5618
Source Clinical Trial Id
5599
Herb2 Clinical Trial Id
HBCT005599
Nct Id
NCT00289445
Title
Study With Mitomycin c/5-FU/FA in Pretreated Gastrointestinal Cancer Patients With Metastases (>= Second-line Treatment)
Status
Completed
Phase
Phase 1|Phase 2
Study Result
No
Study Condition
Gastrointestinal Neoplasms|Neoplasm Metastasis
Study Type
Interventional
Study Design
Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
Intervention
DRUG: Mitomycin C|DRUG: 5-FU|DRUG: Folinic acid
Intervention Allocation
Non_Randomized
Intervention Model
Single_Group
Intervention Mask
Intervention Purpose
Treatment
Gender
All
Age
Adult, Older_Adult
Enrollment
Outcome Measure
maximum tolerated dose (MTD) of bolus mitomycin C (MMC) in combination with 24 h-continuous infusion of 5-fluorouracil (FU) plus folinic acid|toxicity|activity
Sponsor Collaborator
University Hospital Tuebingen
Funded By
OTHER
Location
Other Id
jth_003
Start Date
1999-09
Primary Completion Date
2006-03
Completion Date
2006-03
First Posted
2006-02-09
Results First Posted
Last Update Posted
2013-01-28
Study Document
Study Url
https://clinicaltrials.gov/study/NCT00289445
Title Cn
Title En
Study With Mitomycin c/5-FU/FA in Pretreated Gastrointestinal Cancer Patients With Metastases (>= Second-line Treatment)
Bilingual Status
semi_complete